Dow has completed of the sale of styron division to Bain Capital for $1.63 billion. The company said it elected to retain a 7.5% equity position in Styron. Dow also said the closure has helped the company exceed its goal of divesting $5 billion in non-strategic assets,
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
